Podcast: Beyond Wearables--Profusa CEO Discusses Novel Tiny Injectable Biosensor For Long-Term Monitoring
Executive Summary
In this podcast interview with Medtech Insight, Profusa Inc. Chairman and CEO Ben Hwang discusses the company's long-term biochemical monitoring platform, the first application for its tiny injectable biosensor, and what's next for the company.
You may also be interested in...
Profusa Raised $45M To Market PAD-Monitoring Implant In Europe
Digital Health company Profusa raised more than $45m in a series C financing round. The company plans to use the proceeds to bring its tiny CE-marked injectable biosensors, used to monitor tissue oxygenation in patients with peripheral artery disease, to key opinion leaders and clinicians in Europe.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.